Friday, 16 October 2026European Markets

LATECOERE Stock Went Down By Over 9% So Far On Monday

Loading stream...

(vianews) - shares of latecoere (cac 40: lat.pa) dropped 9.64% to €0.33 at 11:58 est on monday, after two sequential sessions in a row of losses. cac 40 is falling 0% to €0.00, following the last session's downward trend. this seems, up to now, a somewhat bullish trend trading session today.

about latecoere

latécoère s.a. designs, develops, manufactures, and supports aerostructures and interconnection systems in europe, the united states, africa, asia, and internationally. the company manufactures aircraft structural elements, such as aircraft doors; and fuselage components, such as aircraft sections, tail cones, nose cone fairings, etc. it also offers electrical harnesses and wiring interconnection systems, avionics racks, airborne video equipment and systems, and test benches for the aeronautics, defense, and space sectors, as well as cameras, screens, data transmission solutions. the company was founded in 1917 and is headquartered in toulouse, france. latécoère s.a. is a subsidiary of scp skn holding i sas.

earnings per share

as for profitability, latecoere has a trailing twelve months eps of €-2.

volatility

latecoere's last week, last month's, and last quarter's current intraday variation average was a negative 0.49%, a negative 0.10%, and a positive 2.80%.

latecoere's highest amplitude of average volatility was 1.16% (last week), 3.40% (last month), and 2.80% (last quarter).

volume

today's last reported volume for latecoere is 292299 which is 105.07% above its average volume of 142535.

more news about latecoere (lat.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com